All News

Sharon Nachman, MD, division chief for pediatric infectious disease at Stony Brook Children's Hospital, shares her reaction to the court ruling blocking the scaled-back childhood vaccine schedule.

Interoperability gaps in EHRs hinder pharmacists' ability to ensure safe medication practices, impacting patient safety and care transitions.

Dual-target flu immunity to HA and NA halves airborne spread in ferrets without escape mutations, reshaping next-generation vaccines and pharmacist counseling.

Pharmacists play a pivotal role in helping patients align healthy nutritional habits with consistent medication adherence to improve long-term chronic disease outcomes.

New American College of Cardiology/American Heart Association dyslipidemia guidelines reset LDL goals, add PREVENT risk scoring, and expand Lp(a)/apoB testing for earlier, tougher prevention.

Acquiring advanced certifications equips pharmacy technicians with a clear pathway to increased salary potential and long-term financial stability.

Olympic athlete Tabitha Peterson, PharmD, reveals how sports pharmacy helps athletes avoid antidoping risks, manage supplements safely, and stay competition-ready.

Real-world data show racial gaps in multiple myeloma CAR T-cell therapy; pharmacists in oncology can boost referrals, equity, and access.

RUNX1 in microglia helps predict opioid pain relief, higher morphine needs, and withdrawal severity—pointing to genetic screening and safer, personalized pain management.

Daily walking and resistance bands during chemotherapy help curb chemo brain and brain fog, keeping patients active and sharper at home.

Finerenone slows nondiabetic chronic kidney disease, improving eGFR slope and signaling a possible FDA expansion.

Analysis reveals critical price volatility patterns affecting pharmacy inventory management.

A Response to “We Can Do Better: Educating on Perimenopause and Menopause Is a Good Thing,” Published in November 2025

PharmD and Olympian Tabitha Peterson reveals how pharmacy analytics, teamwork, and constant learning fuel elite curling strategy and Olympic-level performance.

The VIVID trial finds high-dose vitamin D3 doesn’t cut COVID care visits but hints at fewer long COVID symptoms.

Explore how pharmacists elevate electrophysiology care and get a preview of ACC 2026 trials on AF, HFpEF, pulmonary embolism, and hypertension.

A federal judge halted HHS Secretary Robert F. Kennedy Jr's rollback of childhood vaccines, freezing ACIP's overhaul and immunization votes amid a medical society lawsuit.

Novo Nordisk's Nicky Kelepouris, MD, discusses the REAL8 trial, the expanded pediatric indications for once-weekly somapacitan, and the pharmacist's role in supporting families navigating long-term growth hormone therapy.

Improved risk stratification for coadministration of linezolid with serotonergic agents has the potential to optimize its indications in clinical practice.

Stopping weight management medications drives rapid weight regain and metabolic rebound—making long-term treatment key to optimal outcomes.

Tabitha Peterson, PharmD, discusses how teamwork, strategy, and antidoping expertise sharpen patient care and athlete safety.

Despite persistent gaps in cardiovascular risk management, pharmacists are proving essential in improving LDL control, guiding statin use, and supporting evidence-based care across clinical settings.

Build financial confidence by making strategic money decisions all year.

ADCs are reshaping metastatic breast cancer and pharmacists' roles in treatment management.

Mass-produced compounded GLP-1 drugs bypass FDA safeguards, raising sterility, quality, and supply-chain risks—putting patients at risk despite ending shortages.

FDA approves secukinumab for adolescents 12 years and older with moderate to severe hidradenitis suppurativa, offering the first IL-17A option and new hope for earlier relief.

FDA expands Arexvy RSV vaccine to at-risk adults 18-49, backed by phase 3b data—what it means for patients and pharmacists.

No FDA-approved oral suspension of valacyclovir currently exists, meaning pharmacies must continue relying on compounded preparations for patients unable to swallow tablets while Hyloris works to resolve the manufacturing issues.